Survival proportions in SCID mice bearing disseminated NHL cells. (A) mAb hLL1 was administered to Raji-bearing SCID mice at 2 dose schedules, both initiated 1 day after tumor cells were inoculated intravenously. Survival was compared with that in untreated Raji-bearing SCID mice. □, 100 μg/injection, 5 times/wk for 2 weeks, then twice weekly; ▴, 350 μg/injection, twice weekly for 2 weeks; •, untreated. (B) Survival of Daudi-bearing SCID mice given a low dose of hLL1 was compared with survival of untreated Daudi-bearing SCID mice. ▴, 25 μg twice-weekly intravenous injections, starting 1 day after injection of tumor cells; •, untreated. Each treatment group contained 10 mice.